Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Essential thrombocythemia.

Guido Finazzi1, Claire Harrison

  • 1Department of Hematology, Ospedali Riuniti, Largo Barozzi 1, 24128 Bergamo, Italy. gfinazzi@ospedaliriuniti.bergamo.it

Seminars in Hematology
|October 8, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Selinexor Plus Ruxolitinib in Janus Kinase Inhibitor-Naïve Myelofibrosis: Phase III SENTRY Trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

Targeted treatment of anemia in myelofibrosis and the impact of JAK inhibitors.

Expert opinion on pharmacotherapy·2026
Same author

Safety of Ready-to-Eat Green Leafy Salads: Growth Potential of <i>Listeria monocytogenes</i> During Shelf Life.

Foods (Basel, Switzerland)·2026
Same author

Myeloproliferative neoplasms with concomitant chronic myeloid leukemia are associated with TKI resistance and poor outcomes.

Leukemia·2026
Same author

POIESIS: a phase III study of add-on navtemadlin in JAK inhibitor-naïve myelofibrosis patients with a suboptimal response to ruxolitinib.

Future oncology (London, England)·2026
Same author

New graduate medication safety preparedness: an Australian cross-sectional and longitudinal qualitative research study.

Frontiers in medicine·2026
Same journal

Pain in SCD-Many mechanisms and mysteries.

Seminars in hematology·2026
Same journal

The many facets of cardiopulmonary complications in sickle cell disease.

Seminars in hematology·2026
Same journal

Clonal hematopoiesis in the setting of sickle cell disease and its relevance to curative therapies.

Seminars in hematology·2026
Same journal

Treatment of myeloproliferative neoplasms: Exploring new horizons of who and when to cytoreduce in patients with polycythemia vera and essential thrombocytosis.

Seminars in hematology·2026
Same journal

Telomeres biology disorders: the past, the present and the future.

Seminars in hematology·2026
Same journal

Cardiovascular complications in patients with myeloproliferative neoplasms: What hematologists need to know.

Seminars in hematology·2026
See all related articles

Essential thrombocythemia (ET) diagnosis needs updated criteria. Management focuses on risk stratification and preventing complications, with hydroxyurea (HU) plus aspirin for high-risk patients.

Area of Science:

  • Hematology
  • Oncology
  • Molecular Pathogenesis

Background:

  • Essential thrombocythemia (ET) and Philadelphia chromosome-negative myeloproliferative disorders (MPDs) have seen recent advances in understanding molecular pathogenesis.
  • Current ET diagnosis relies on outdated exclusion criteria, lacking integration of recent scientific discoveries.
  • ET is associated with increased thrombotic and hemorrhagic risks and potential progression to myelofibrosis or acute myeloid leukemia (AML).

Purpose of the Study:

  • To review the current understanding of ET molecular pathogenesis.
  • To highlight the limitations of existing diagnostic criteria for ET.
  • To discuss current management strategies, including risk stratification and therapeutic options for ET.

Main Methods:

  • Review of recent scientific literature on ET and MPDs.

Related Experiment Videos

  • Analysis of diagnostic criteria and their limitations.
  • Evaluation of current therapeutic approaches and their associated risks.

    • Main Results:

    • Despite progress in understanding MPDs, ET diagnosis remains based on historical exclusion criteria.
    • ET management necessitates risk stratification to guide treatment decisions.
    • Hydroxyurea (HU) plus aspirin is supported for high-risk ET patients, with anagrelide or interferon-alpha (IFN-alpha) as second-line options.

    Conclusions:

    • There is a need to update ET diagnostic criteria incorporating recent molecular insights.
    • Risk-adapted management is crucial for ET patients to mitigate vascular events and transformation.
    • Therapeutic choices for ET should consider patient risk, response to treatment, and specific situations like pregnancy (IFN-alpha preference).